Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT05249543
Active, not recruiting Not applicable

Transdiagnostic Versus Diagnosis-specific Cognitive-behavioral Therapy

NCT05249543 · tracked via the Priya Life Science Sweden tracker
Sponsor
Karolinska Institutet
Phase
Not applicable
Started
2022-03-01
Last updated
2026-03-24

Condition(s) studied

Panic DisorderGeneralized Anxiety DisorderSocial Anxiety DisorderObsessive-Compulsive DisorderPosttraumatic Stress Disorder

Investigational drug(s) / intervention(s)

Unified protocolDiagnosis-specific cognitive-behavioral therapy

Unified protocol: Transdiagnostic cognitive-behavioral therapy

Diagnosis-specific cognitive-behavioral therapy: Diagnosis-specific cognitive-behavioral therapy

Study summary

The primary aim of the pilot study is to investigate the feasibility of conducting a randomized controlled trial (RCT) comparing the effects of transdiagnostic and diagnosis-specific cognitive-behavioral therapy (CBT) for patients with anxiety disorders in routine psychiatric outpatient care in Stockholm, Sweden. It is hypothesized that an RCT is feasible in terms of recruitment, retention, therapist competence and adherence to treatments, and that the treatments are well received by participants.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * 18-65 years of age, * Being able to speak Swedish without interpreter support, * A principal diagnosis of panic disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, or posttraumatic stress disorder, and * Pharmacological treatment (if any) that is stable six weeks prior to treatment start Exclusion Criteria: * Current diagnosis of psychotic disorder, bipolar disorder, or moderate to severe substance use disorder, * Moderate to severe risk of suicide, * Psychiatric, somatic, or social problems which require other management or intervention than cognitive-behavioral therapy, and * Other simultaneous psychological treatment

Primary outcome measure(s)

  • Feasibility measure 1 — Prior to pre assessment, up to 1 month
    Recruitment of participants: the number of participants per diagnosis included in the study
  • Feasibility measure 2 — During treatment, up to 18 weeks
    Attrition: the number of participants dropping out of treatment
  • Feasibility measure 3 — Prior to pre assessment, up to 6 months
    Therapist competence in and adherence to the unified protocol according to the UP Adherence and Competence Scale, and diagnosis-specific cognitive-behavioral therapy according to the Cognitive Therapy Scale-Revised
  • Feasibility measure 4 — During treatment Week 2
    Treatment credibility and expectancy of improvement according to the Credibility/Expectancy Questionnaire
  • Feasibility measure 5 — At post assessment, up to 18 weeks
    Treatment satisfaction according to the Client Satisfaction Questionnaire
  • Feasibility measure 6 — At post assessment, up to 18 weeks
    Adverse effects according to the Negative Effects Questionnaire

Trial sites (1)

FacilityCityRegionStatus
WeMind Stockholm Sweden

More Karolinska Institutet trials in Sweden

Effects of Individual Tailored Physical Exercise in Patients With POTS After COVID-19 - a Randomized Controlled Study Active, not recruiting
Implementation of Evidence-based Guidelines for Assessment and Counseling of Patients With Neck and Back Pain in Health Care Centers Starting soon
Single Nuclei Sequencing in Human Skeletal Muscle After Unloading Enrolling by invitation
Validation of a Novel Smartphone-based Method for Heart Rhythm Monitoring in the Home Environment Active, not recruiting
Omission of Axillary Lymph Node Dissection in Case of Tumor Spread to Lymph Nodes in the Armpit in Breast Cancer Recruiting

Other trials for the same condition

Efficacy of Internet-delivered Trauma-focused CBT for Young People With PTSD Recruiting
Metacognitive Therapy for Depression and Generalized Anxiety Disorder in Primary Care, Blended Version of Mediated Treatment Enrolling by invitation
Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement Enrolling by invitation
Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders Recruiting
European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05249543 on ClinicalTrials.gov ↗ ← All trials in Sweden